Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial arrhythmogenic disorder associated with mutations in the cardiac ryanodine receptor (RyR2) and cardiac calsequestrin (CASQ2) genes. Previous in vitro studies suggested that RyR2 and CASQ2 interact as parts of a multimolecular Ca 2ϩ -signaling complex; however, direct evidence for such interactions and their potential significance to myocardial function remain to be determined. We identified a novel CASQ2 mutation in a young female with a structurally normal heart and unexplained syncopal episodes. This mutation results in the nonconservative substitution of glutamine for arginine at amino acid 33 of CASQ2 (R33Q). Adenoviral-mediated expression of CASQ2 R33Q in adult rat myocytes led to an increase in excitationcontraction coupling gain and to more frequent occurrences of spontaneous propagating (Ca 2ϩ waves) and local Ca 2ϩ signals (sparks) with respect to control cells expressing wild-type CASQ2 (CASQ2 WT ). As revealed by a Ca 2ϩ indicator entrapped inside the sarcoplasmic reticulum (SR) of permeabilized myocytes, the increased occurrence of spontaneous Ca 2ϩ sparks and waves was associated with a dramatic decrease in intra-SR [Ca 2ϩ ]. Recombinant CASQ2 WT and CASQ2 R33Q exhibited similar Ca 2ϩ -binding capacities in vitro; however, the mutant protein lacked the ability of its WT counterpart to inhibit RyR2 activity at low luminal [Ca 2ϩ ] in planar lipid bilayers. We conclude that the R33Q mutation disrupts interactions of CASQ2 with the RyR2 channel complex and impairs regulation of RyR2 by luminal Ca 2ϩ . These results show that intracellular Ca 2ϩ cycling in normal heart relies on an intricate interplay of CASQ2 with the proteins of the RyR2 channel complex and that disruption of these interactions can lead to cardiac arrhythmia. (Circ Res. 2006;98:1151-1158.) Key Words: calsequestrin Ⅲ ryanodine receptor Ⅲ sarcoplasmic reticulum Ⅲ Ca 2ϩ -induced Ca 2ϩ release Ⅲ catecholaminergic polymorphic ventricular tachycardia Original
C atecholaminergic polymorphic ventricular tachycardia (CPVT) (Online Mendelian Inheritance in Man no. 604772) is a familial arrhythmogenic disorder characterized by adrenergically mediated polymorphic ventricular tachyarrhythmias, leading to syncope and sudden cardiac death in individuals with structurally normal hearts. 1 The episodes of tachyarrhythmia are typically triggered by physical exercise or emotional stress. Two genetic variants of the disease have been described: a recessive form associated with homozygous mutations in the gene encoding the cardiac isoform of calsequestrin (CASQ2) 2,3 and a second form transmitted as an autosomal dominant trait associated with mutations in the gene encoding the cardiac ryanodine receptor (RyR2). 4, 5 The contractile machinery of cardiac myocytes becomes activated when Ca 2ϩ enters the sarcoplasmic reticulum (SR) via L-type Ca 2ϩ channels and triggers a process termed Ca 2ϩ -induced Ca 2ϩ release (CICR) from the SR. 6 Whereas CICR controls the release process from the cytosolic side, a second Ca 2ϩ -dependent mechanism controls the activity of the Ca 2ϩ -release channels from the SR lumen. Specifically, the decline of intra-SR [Ca 2ϩ ] that accompanies the Ca 2ϩrelease process contributes to Ca 2ϩ -release termination, a mechanism referred to as luminal Ca 2ϩ -dependent deactivation. [7] [8] [9] The Ca 2ϩ -release channel is present in the junctional SR membrane in the form of a quaternary complex composed of RyR2, triadin, junctin, and CASQ2. 10, 11 The integral membrane proteins triadin and junctin physically interact with RyR2 and link the Ca 2ϩ -binding protein CASQ2 to the complex. Ca 2ϩ -dependent interactions of CASQ2 with the RyR2-triadin complex are thought to provide a molecular basis for regulation of RyR2 channel by luminal Ca 2ϩ . 12, 13 In addition, CASQ2 monomers can form polymers with high Ca 2ϩ -binding capacities that are essential for the Ca 2ϩ storage function of the SR. 14, 15 To date, 4 homozygous sequence variations in the CASQ2 gene have been identified in patients with CPVT (see Inherited Arrhythmias Database at http://pc4.fsm.it:81/cardmoc). 2, 3 The precise molecular basis for the alterations in Ca 2ϩ handling in cells expressing CPVT-linked CASQ2 mutants remains to be determined. To date, the effect of only 1 of these mutations on CASQ2 activity and function has been examined. 16, 17 These studies focused on a CASQ2 mutant protein in which aspartate 307 is changed to histidine (CASQ2 D307H ) and suggested that the CASQ2 D307H protein is compromised in its ability to facilitate the Ca 2ϩ storing and releasing functions of the SR. These effects may be a consequence of a reduction in the Ca 2ϩ -binding capacity of the mutant protein or altered interactions between CASQ2 D307H and components of the RyR2 channel complex. 16, 17 Furthermore, it is unknown how independent mutations in the CASQ2 and RyR2 genes result in similar clinical manifestations in CPVT. In the present study, we report the identification of a new mutation in the CASQ2 gene in a patient with CPVT. We also demonstrate that this mutation alters the functional interactions between CASQ2 and the RyR2 channel complex, resulting in abnormal luminal Ca 2ϩ -dependent regulation of the RyR2 channel.
Materials and Methods
CPVT in human patients was diagnosed using standard cardiologic tests. Genetic analyses of the CPVT patients were performed using a combination of methods of PCR, single-strand conformation polymorphism (SSCP) analysis, and denaturing high-performance liquid chromatography (DHPLC) (Wave Transgenomics). The cellular effects of the newly identified CPVT-linked CASQ2 mutation were studied in isolated adult rat ventricular myocytes infected with adenoviruses for expression of either the wild-type (WT) or mutant forms of CASQ2. Cytosolic and intra-SR [Ca 2ϩ ] changes were monitored using confocal microscopy, and whole cell currents were recorded with the patch-clamp technique. In vitro single-RyR2 channel recordings and CASQ2 Ca 2ϩ -binding measurements were performed.
An expanded Materials and Methods section can be found in the online data supplement available at http://circres.ahajournals.org.
Results

Identification of a Novel CPVT-Associated Mutation in CASQ2
The CASQ2 coding sequence from a patient diagnosed with CPVT revealed the presence of a previously unidentified sequence alteration (online data supplement). This alteration changed codon 33 of CASQ2 from CGA to CAA and resulted in the nonconservative substitution of glutamine for arginine (R33Q). This residue is located within a conserved region of CASQ2, and this position in the related CASQ1 protein is also occupied by arginine in all CASQ2 and CASQ1 sequences available in public databases (Figure I in the online data supplement). Analysis of the domain structures of CASQ2 and particularly CASQ1 suggest that this residue is located in a domain involved in protein-protein interactions that may participate in the formation of CASQ polymers or interactions with other components of the junctional complex. 10, 15, 18 Interestingly, a different mutation in this codon was previously reported that resulted in a stop codon in place of the arginine residue, 3 suggesting it may represent a relatively frequently mutated genomic location.
Electrophysiological Recordings and Intracellular Ca 2؉ Transients in Myocytes Expressing CASQ2 R33Q
CASQ2 is a major intracellular Ca 2ϩ -binding protein that plays a key role in cardiac excitation-contraction (EC) coupling. To test whether the R33Q substitution in CASQ2 caused substantial changes in EC coupling and intracellular Ca 2ϩ handling, we examined the effects of overexpressing the CASQ2 R33Q protein on a series of electrophysiological and intracellular Ca 2ϩ -handling parameters in rat ventricular myocytes. In these experiments, cultured myocytes were infected with adenoviral vectors engineered to direct the expression of either human CASQ2 WT or CASQ2 R33Q . An adenovirus containing a nontranslatable fragment of CASQ2 sequence was used as an infection control. We have previously used this experimental strategy to characterize the effects of a different CPVT-associated CASQ2 mutant protein on myocyte function. 16 In agreement with our earlier studies, immunoblot analysis revealed that this infection protocol resulted in a Ϸ3-fold increase in total CASQ2 protein levels in cells infected with either the CASQ2 WT or CASQ2 R33Q adenovirus, whereas the control virus did not affect CASQ2 levels ( Figure  1 ). The increase in total CASQ2 abundance was caused by expression of the mutant protein because endogenous protein levels remained unchanged in CASQ2 R33Q cells, as determined by an antibody that recognizes the rat but not the human form of CASQ2.
Initially, the effects of CASQ2 R33Q expression on SR Ca 2ϩ handling and release were tested. The total SR Ca 2ϩ content of control myocytes, or myocytes expressing CASQ2 WT or CASQ 2R33Q , was assessed from the amplitude of the Ca 2ϩ transients and the integral of Na/Ca 2ϩ exchange current (I NCX ) Figure 1 . Immunoblot analysis of calsequestrin levels in myocytes infected with Ad-Control, Ad-CASQ2 WT , and Ad-CASQ2 R33Q vectors. A, Representative Western blot of total CASQ2 (rat and human) (top) and rat CASQ2 alone (bottom). B, Normalized optical density for rat and total CASQ2. Comparisons were performed by using 1-way ANOVA. *Significance was defined at PϽ0.05 (nϭ8 and 5 for total and rat CASQ2, respectively). The measurements were performed 48 to 56 hours after infection of myocytes with the Adv constructs.
evoked by the application of caffeine. Although, ectopic expression of the WT protein resulted in a dramatic increase in SR Ca 2ϩ content, no statistically significant changes in SR Ca 2ϩ content were observed with expression of CASQ2 R33Q (Figure 2A and 2B).
Next, the effects of overexpression of CASQ WT and CASQ2 R33Q on Ca 2ϩ release during EC coupling were compared in myocytes undergoing voltage clamp stimulation. The amplitude of the I Ca -induced Ca 2ϩ transients was similarly increased Ϸ30% in myocytes overexpressing both forms of CASQ2 ( Figure 3 and supplemental Table I ). However, whereas the duration of the rising phase of the Ca 2ϩ transients was slowed in CASQ2 WT -overexpressing cells, Ca 2ϩ transient rise was accelerated in CASQ2 R33Q -expressing myocytes (supplemental Table I ). Additionally, expression of CASQ2 WT and CASQ2 R33Q had opposite effects on the gain of CICR (ie, Ca 2ϩ -release rate for a given Ca 2ϩ trigger and a given SR Ca 2ϩ content), a term that characterizes the efficiency of I Ca to elicit Ca 2ϩ release. Whereas overexpression of WT CASQ2 resulted in a decreased gain of CICR, expression of the mutant form of the protein increased CICR gain ( Figure 3C , inset). Therefore, expression of CASQ2 R33Q enhanced the functional activity of the Ca 2ϩ -release mechanism with respect to both control myocytes and myocytes overexpressing the WT form of the protein.
Because the potentiating effects of R33Q on the Ca 2ϩ -release mechanism occurred on the background of a full set of native CASQ, they can be qualified as "dominant positive" effects. In general, these effects strongly suggest that the mutant protein disrupts protein-protein interactions involved in control of the SR Ca 2ϩ -release process.
Periodic Pacing
CPVT is associated with ventricular tachycardia, particularly in response to adrenergic stimulation, and thus we next examined whether CASQ2 R33Q expression would affect electrical and intracellular Ca 2ϩ signals in rhythmically paced cardiac myocytes. Periodic Ca 2ϩ transients and action potentials (APs) were compared in myocytes overexpressing CASQ2 WT and CASQ2 R33Q undergoing rhythmic stimulation in the absence or presence of isoproterenol (ISO). In control and CASQ2 WT -overexpressing myocytes, we observed stable, rhythmic Ca 2ϩ transients and APs both in the absence and presence of ISO (1 mol/L; 8 and 6 experiments, respectively; not shown). In the absence of ISO, CASQ2 R33Q myocytes also showed only regular AP-induced Ca 2ϩ transients. However, following exposure to 0.01 to 1 mol/L ISO, these cells developed characteristic disturbances in Ca 2ϩ release and electrical activity manifested as extrasystolic Ca 2ϩ transients, delayed afterdepolarizations (DADs), and irregular APs (Figure 4 and supplemental Figure IV) . The percentage of cells exhibiting such disturbances increased with increasing ISO concentration (from Ϸ30% at 0.01 mol/L to a maximum of 80% at 0.2 to 1 mol/L ISO).
Ca 2؉ Sparks and Waves
To further understand the effects of CASQ2 R33Q on the Ca 2ϩ -release mechanism, we measured spontaneous local (sparks) and global (waves) Ca 2ϩ signals in saponin-permeabilized myocytes maintained at a constant cytosolic [Ca 2ϩ ] (Ϸ75 nmol/L). Consistent with earlier results, overexpression of CASQ2 WT resulted in an increase in the magnitude and slowing of the kinetics of Ca 2ϩ sparks without significantly changing the frequency of events ( Figure 5A through 5D and supplemental Table II ). In contrast, although overexpression of CASQ R33Q did not alter the amplitude of Ca 2ϩ sparks, it did increase their frequency ( Figure 5A through 5D). The kinetics of the local events in R33Q myocytes, however, did not change with respect to control cells ( Figure 5 and supplemental Table II ).
Next, the consequences of overexpression of CASQ2 WT and CASQ2 R33Q on the periodic occurrence of spontaneous Ca 2ϩ waves were compared in myocytes incubated in a bathing solution containing 75 nmol/L Ca 2ϩ and 100 mol/L EGTA. Under these conditions, overexpression of CASQ2 WT dramatically reduced wave frequency, whereas overexpression of CASQ2 R33Q caused an increase in Ca 2ϩ wave occurrence ( Figure 5E and supplemental Table III ). As with I Ca -induced Ca 2ϩ transients (see Figure 3 and supplemental Table I), the amplitude of spontaneous Ca 2ϩ transients was increased in both CASQ2 WT and CASQ2 R33Q -overexpressing myocytes, and the kinetics of Ca 2ϩ transients were slowed in CASQ2 WT but accelerated in CASQ2 R33Q cells ( Figure 5E and supplemental Table III ). Of note, expression of CASQ2 R33Q also resulted in an increase in the frequency of Ca 2ϩ sparks and waves in intact myocytes loaded with fluo-3 acetoxymethyl ester (fluo-3 AM) (supplemental Table VI and supplemental Figure II) , indicating that the observed CASQ2 R33Qinduced changes in Ca 2ϩ signals were not attributable to myocyte permeabilization. These results suggest that expression of CASQ2 R33Q enhances the propensity for spontaneous Ca 2ϩ release from the SR, apparently by increasing the functional activity of the RyR2 channels.
Intra-SR [Ca 2؉ ]
Given the 2 potential functions of CASQ2 (ie, as a Ca 2ϩbinding protein and as a modulator of the RyR2 channel), expression of the R33Q mutant could influence the total amount of Ca 2ϩ stored in the SR by changing SR Ca 2ϩ buffering and/or by affecting Ca 2ϩ leak through RyR2s. To distinguish between these mechanisms, we performed measurements of free [Ca 2ϩ ] inside the SR ([Ca 2ϩ ] SR ). The total resting SR luminal [Ca 2ϩ ] is determined by both Ca 2ϩ transport across the SR membrane and Ca 2ϩ binding to luminal buffers. On the other hand, owing to the finite nature of the SR Ca 2ϩ store, the steady-state free SR [Ca 2ϩ ] is independent of the concentration of intra-SR Ca 2ϩ -binding sites and is solely governed by a balance between Ca 2ϩ leak and Ca 2ϩ uptake across the SR membrane. Therefore, potential changes in free basal [Ca 2ϩ ] SR should provide good indications for altered RyR2 activity. [Ca 2ϩ ] SR was monitored by the low-affinity Ca 2ϩ indicator fluo-5N loaded into the SR. The cytosolic Ca 2ϩ signal was recorded simultaneously using the Ca 2ϩ dye rhod-2. In comparison with control cells, the basal [Ca 2ϩ ] SR was significantly reduced in CASQ2 R33Q myocytes, as evidenced by the reduced intensity of the SRentrapped fluo-5N ( Figure 6 ). Additionally, the amplitudes of the Ca 2ϩ -depletion signals during waves were diminished in CASQ2 R33Q -expressing myocytes ( Figure 6 and supplemental IV). Importantly, fluo-5N fluorescence in both cell types was similar after depletion of the SR Ca 2ϩ store by caffeine (supplemental Table IV ), indicating that the changes in fluo-5N fluorescence in Ca 2ϩ -loaded SR reflected true changes in [Ca 2ϩ ] SR . The reduced [Ca 2ϩ ] SR is CASQ2 R33Q myocytes suggests that SR Ca 2ϩ leak was enhanced in these cells, consistent with the increased frequency of spontaneous Ca 2ϩ sparks. Similar to intact myocytes (Figure 2) , the amplitude of the cytosolic spontaneous and caffeine-induced Ca 2ϩ transients was preserved in permeabilized CASQ2 R33Q myocytes despite the reduction of [Ca 2ϩ ] SR (Figure 6B through 6D). The ability of the CASQ2 R33Q myocytes to maintain the amplitude of their Ca 2ϩ transients despite the reduced [Ca 2ϩ ] SR is attributable to increased intrastore Ca 2ϩ buffering (ie, an increased concentration of Ca 2ϩ -binding sites that can bind and release Ca 2ϩ on discharge of the store) in myocytes overexpressing CASQ2 R33Q . Collectively, these results suggest that CASQ2 R33Q expression resulted in both increased leak of Ca 2ϩ through the RyR2 and increased intra-SR Ca 2ϩ -buffering capacity.
Effects of CASQ WT and CASQ2 R33Q on Single-RyR2 Channel Activity
CASQ2 has been shown to inhibit the functional activity of the RyR2 channel complex. 12 To directly examine the effect of the R33Q mutation on the ability of CASQ2 to influence RyR2 behavior, we performed single-RyR2 channel recordings using the planar lipid bilayer technique (Figure 7) . Cardiac SR vesicles were incorporated into planar lipid bilayers, and the activity of single-RyR2 channels was measured using Cs ϩ as the charge carrier. 12 In these experiments, single RyR2s were stripped of endogenous CASQ2 by exposing the luminal side of the channel to 5 mmol/L Ca 2ϩ . This treatment promoted efficient dissociation of CASQ2, as evidenced by the enhanced RyR2 activity that persisted after the [Ca 2ϩ ] in the trans (luminal) chamber was reduced to the initial low level. Consistent with our previous studies, 12 addition of CASQ2 WT to the RyR2 complex resulted in a reduction in RyR2 activity. In contrast, addition of CASQ2 R33Q to the RyR2 complex did not produce a similar inhibitory effect. Interestingly, subsequent addition of CASQ2 WT (in the continuous presence of CASQ2 R33Q ) did not restore RyR2 open probability (P o ) to that observed with CASQ2 WT alone (supplemental Figure V) . Therefore, the substitution of glutamine for arginine at amino acid 33 of CASQ2 appears to compromise the ability of the protein to modulate the functional activity of the RyR2 channel. Moreover, the R33Q mutant seems to impair the functional interactions of the WT protein with the RyR2 complex, consistent with the dominant positive effects of the mutant on SR Ca 2ϩ release. 
Determination of Ca 2؉ -Binding Affinities of Recombinant CASQ2 WT and CASQ2 R33Q
In principle, the pathological effects of the R33Q mutation could be attributable to alterations in the Ca 2ϩ -binding properties of the mutant protein. We, therefore, tested whether the CASQ2 R33Q protein displayed altered Ca 2ϩ -binding affinities when compared with CASQ2 WT using Ca 2ϩ overlay experiments. 19 Two kinetic parameters of Ca 2ϩ binding, the Ca 2ϩ affinity (K d ) and capacity (B max ), were calculated and are shown in supplemental Table V . Both values were comparable for the two proteins and were in agreement with previous values reported for native CASQ2 WT . 20 Thus the effects of the R33Q mutation in CASQ2 function appears to be unrelated to changes in Ca 2ϩ binding.
Discussion
Genetic defects in the SR Ca 2ϩ -handling proteins RyR2 and CASQ2 have been linked to CPVT, a familial disease that predisposes young individuals with structurally normal hearts to sudden cardiac death. In this study, we report on a novel CPVT-linked mutation in CASQ2 that results in the nonconservative substitution of glutamine for arginine at amino acid 33. Using a combination of cellular and in vitro techniques, we demonstrate that ectopic expression of the mutant protein in cardiac myocytes increased the functional activity of the RyR2 channel, thereby increasing the rate of Ca 2ϩ leak from the SR and enhancing the propensity of SR Ca 2ϩ release to be spontaneously activated.
Molecular Mechanisms of R33Q
The potentiatory effects of CASQ2 on the Ca 2ϩ -release channels were evidenced by the following findings. Expression of CASQ2 R33Q resulted in a shortening of the activation kinetics of Ca 2ϩ transients, and increased CICR gain compared with control myocytes or myocytes overexpressing CASQ2 WT . Additionally, the frequency of spontaneous Ca 2ϩ sparks and waves were increased in myocytes expressing CASQ2 R33Q . These changes in focal and global cytosolic Ca 2ϩ transients were accompanied by a dramatic decrease in intra-SR [Ca 2ϩ ], consistent with an increase in the leak of Ca 2ϩ through RyR2s in CASQ2 R33Q -expressing cells. The consequences of expressing CASQ2 R33Q on Ca 2ϩ handling were clearly different from the effects of expressing the CASQ2 D307H mutant protein, the only other CPVT-linked CASQ2 mutation that has been characterized at the cellular and molecular level thus far. 16, 17 In those earlier studies, ectopic expression of CASQ2 D307H in myocytes led to decreases in both active SR Ca 2ϩ release and SR Ca 2ϩ content. 16, 17 These effects were attributed to disruptions of the CASQ2 polymerization 16 that is required for high-capacity Ca 2ϩ binding, although in vitro binding studies also indicated that the mutant protein interacted more weakly with triadin and junctin. 17 Several key pieces of experimental data from our study suggest that CASQ2 R33Q exerts its effects by disrupting protein-protein interactions within the RyR2 complex rather than by compromising the Ca 2ϩ -binding capacity of CASQ2. The free [Ca 2ϩ ] in the SR lumen at steady state is determined by the balance of Ca 2ϩ leakage and uptake across the SR membrane and should not be influenced by the concentration of Ca 2ϩ -binding sites inside the SR. Therefore, the reduced [Ca 2ϩ ] SR combined with the increased spark frequency observed in CASQ2 R33Q -expressing myocytes strongly suggests that RyR2 activity was enhanced independent of any changes in the intra SR Ca 2ϩ -buffering capacity. Planar lipid bilayer experiments provided further evidence for altered interactions of CASQ2 R33Q with the RyR2 channel complex. In this system, the inclusion of CASQ2 WT decreases the open probability of RyR2 channels, presumably via interactions with triadin or junctin (present study and others 12, 21 ). However, the R33Q mutation abolished the ability of CASQ2 to inhibit RyR2 activity.
At the same time, the total SR Ca 2ϩ content (judged from the size of caffeine-induced Ca 2ϩ transients) was preserved in cells expressing CASQ2 R33Q , indicating that the concentration of Ca 2ϩ -binding sites in the SR increased, as would be expected if the mutant protein maintained its Ca 2ϩ -binding function. Similarly, the mutation did not affect the ability of CASQ2 to bind Ca 2ϩ in vitro. Thus, it appears that the R33Q mutation alters intracellular Ca 2ϩ handling by compromising interactions of CASQ2 with the RyR2 complex without affecting CASQ2 Ca 2ϩ -binding function. Consistent with this conclusion, the N-terminal region of CASQ2, which contains a high proportion of negatively and positively charged amino acids, has been proposed to interact with KEKE motifs in triadin and/or junctin by forming "polar zippers." 10, 18 
Implications for Pathophysiology of CPVT
Similar to other genetic forms of CPVT, 16, 22 the cellular mechanisms of arrhythmia caused by the R33Q mutation involved spontaneous discharges of the SR Ca 2ϩ stores followed by DADs and extrasystolic action potentials ( Figure  4 ). Spontaneous SR Ca 2ϩ release in cardiac myocytes is commonly associated with increased SR Ca 2ϩ load [23] [24] [25] and stimulatory effects of high luminal [Ca 2ϩ ] on the open probability of RyR2 channels. 26 Our results indicated that in CASQ2 R33Qexpressing myocytes the predisposition of SR to spontaneous discharges was increased because of enhanced responsiveness of the release mechanism to luminal Ca 2ϩ .
It is interesting to note that although expression of CASQ2 R33Q produced clear changes in Ca 2ϩ handling and electrical activity in myocytes expressing the full set endogenous CASQ2, CPVT does not develop in the heterozygous carriers of the R33Q mutation; in fact, none of the heterozygous carriers in the study developed ventricular arrhythmias. This lack of a clinical phenotype in the heterozygous carriers could be attributable to the lower ratio of CASQ2 R33Q to the WT protein in these human subjects (presumably Ϸ1:1) when compared with our myocyte experiments (Ϸ2:1), leading to less-profound changes in Ca 2ϩ handling than in myocytes. In support of this notion, expression of the mutant protein at levels similar to those of the endogenous protein (ie, at a ratio of 1:1; supplemental Figure III) did not result in changes in Ca 2ϩ handling observed with higher mutant expression. However, we note that our rat myocyte model can be taken as only an approximate representation of the results of mutant protein expression during human disease. Species-related differences in intracellular Ca 2ϩ handling and membrane excitability, the likely presence of compensatory mechanisms in human disease but not during the acute myocyte experiments, and differences in adrenergic stimulation are only some of the factors that may complicate such a comparison.
Abnormal Modulation of RyR2 Channels by Luminal Ca 2؉ as a Common Mechanism for Various Genetic Forms of CPVT
To date, 4 mutations in the CASQ2 gene have been linked to CPVT. 2, 3 In addition, a number of mutations in the RyR2 gene have been reported to be associated with CPVT. 27 Although the primary molecular alterations caused by the various genetic defects differ, they are likely to converge on a common pathogenic pathway to cause CPVT. Growing evidence indicates that abnormal modulation of RyR2 by luminal Ca 2ϩ might be a common pathogenic factor in these genetically distinct forms of CPVT; however, clear proof of such a common mechanism is lacking. Mutations in CASQ2 that compromise either CASQ2 expression or its Ca 2ϩbinding ability reportedly act on RyR2 indirectly by altering the dynamics of free Ca 2ϩ in the vicinity of the channel, hence accelerating the channel recovery from a luminal Ca 2ϩdependent refractory state. 8, 16, 28 The effects of CPVTassociated RyR2 mutations have been ascribed to either dissociation of FKBP12.6 from the RyR2 causing changes in RyR2 gating 29 (but see George et al 30 ) or, more recently, to changes in RyR2 sensitivity to luminal Ca 2ϩ . 31, 32 Our present findings clearly show that the R33Q mutation disrupts interactions of CASQ2 with the RyR2 complex, thereby sensitizing the release mechanism to activation by luminal Ca 2ϩ . We propose that CPVT can be caused by genetic defects in any component of the luminal Ca 2ϩ -signaling pathway, including steps involved in (1) controlling and sensing free Ca 2ϩ in the vicinity of RyR2, (2) transmitting the luminal Ca 2ϩ change signal to RyR2, and (3) RyR2-gating conformations. Our results strongly support a concept of abnormal luminal regulation as a common mechanism for genetically-distinct forms of CPVT.
Conclusions
In conclusion, our results show that substitution of glutamine for arginine at amino acid 33 of CASQ2 is a naturally occurring mutation that leads to CPVT in homozygous carriers. The underlying molecular mechanism of this mutation appears to involve disrupted interactions of CASQ2 with the proteins of the RyR2 Ca 2ϩ -release complex, resulting in enhanced sensitivity of the RyR2 channel to activation by luminal Ca 2ϩ . The enhanced responsiveness of RyR2s to luminal Ca 2ϩ in turn leads to the generation of extrasystolic spontaneous Ca 2ϩ transients, DADs, and arrhythmogenic action potentials in myocytes expressing CASQ2 R33Q . These results show that intracellular Ca 2ϩ cycling in the normal heart relies on an intricate interplay of CASQ2 with the proteins of the RyR2 channel complex and that disruption of these interactions can lead to cardiac arrhythmias.
